Evidence map›Paper›PMID 42026063›Full record

ArticleNature communications2026

Single cell transcriptional evolution of myeloid leukemia of Down syndrome.

Mi K Trinh, Konstantin Schuschel, Hasan Issa, Rebecca Thomas, Conor Parks, Agnes Oszlanczi, Toochi Ogbonnah, Di Zhou, Lira Mamanova, Elena Prigmore and 15 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Mi K TrinhWellcome Sanger Institute, Hinxton, UK.ORCID 0000-0003-4185-0071
Konstantin SchuschelDepartment of Pediatrics, Goethe University Frankfurt, Frankfurt, Germany.
Hasan IssaDepartment of Pediatrics, Goethe University Frankfurt, Frankfurt, Germany.
Rebecca ThomasGreat Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
Conor ParksWellcome Sanger Institute, Hinxton, UK.ORCID 0000-0003-0240-0684
Agnes OszlancziWellcome Sanger Institute, Hinxton, UK.ORCID 0000-0001-6148-6591
Toochi OgbonnahWellcome Sanger Institute, Hinxton, UK.
Di ZhouWellcome Sanger Institute, Hinxton, UK.
Lira MamanovaWellcome Sanger Institute, Hinxton, UK.ORCID 0000-0003-1463-8622
Elena PrigmoreWellcome Sanger Institute, Hinxton, UK.ORCID 0000-0001-8870-0316
Emilia R RobertsonGreat Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
Angus HodderWellcome Sanger Institute, Hinxton, UK.
Anna WengerWellcome Sanger Institute, Hinxton, UK.ORCID 0000-0001-6063-5401
Nathaniel D AndersonWellcome Sanger Institute, Hinxton, UK.ORCID 0000-0003-4523-6327
Holly J WhitfieldWellcome Sanger Institute, Hinxton, UK.ORCID 0000-0002-7282-387X
Taryn D TregerWellcome Sanger Institute, Hinxton, UK.
José Gonçalves-DiasDepartment of Pediatrics, Goethe University Frankfurt, Frankfurt, Germany.
Karin StraathofGreat Ormond Street Hospital for Children NHS Foundation Trust, London, UK.ORCID 0000-0001-9673-8568
David O'ConnorGreat Ormond Street Hospital for Children NHS Foundation Trust, London, UK.ORCID 0000-0003-3542-5976
Matthew D YoungWellcome Sanger Institute, Hinxton, UK.
Laura JardineWellcome Sanger Institute, Hinxton, UK.ORCID 0000-0003-4495-8205
Stuart AdamsGreat Ormond Street Hospital for Children NHS Foundation Trust, London, UK.ORCID 0000-0002-2650-2848
Jan-Henning KlusmannDepartment of Pediatrics, Goethe University Frankfurt, Frankfurt, Germany. Klusmann@leukemia-research.de.
Jack BartramGreat Ormond Street Hospital for Children NHS Foundation Trust, London, UK. Jack.Bartram@gosh.nhs.uk.ORCID 0000-0003-1573-2506
Sam BehjatiWellcome Sanger Institute, Hinxton, UK. sb31@sanger.ac.uk.ORCID 0000-0002-6600-7665

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) DFG, KL 2374/8-1Wellcome Trust (Wellcome) 223135/Z/21/ZWellcome Trust (Wellcome) WT206194
6 · The paper itself

Abstract

Children with Down syndrome have a 150-fold increased risk of developing myeloid leukaemia (ML-DS). Unusually for a childhood leukaemia, ML-DS arises from a preleukaemic state, termed transient abnormal myelopoiesis (TAM), via a conserved sequence of mutations. Here, we examine the relationship between the genetic and transcriptional evolution of ML-DS from natural variation; a rich collection of primary patient samples and foetal tissues with a range of constitutional karyotypes. We distil transcriptional consequences of each genetic step in ML-DS evolution, utilising single-cell mRNA sequencing, complemented by phylogenetic analyses in progressive disease. We find that transcriptional changes induced by the TAM-defining GATA1 mutations are retained in, and account for most of the ML-DS transcriptome. The GATA1 transcriptome pervades all stages of ML-DS, including progressive disease that had undergone genetic evolution. Our approach delineates the transcriptional evolution of ML-DS and provides an analytical blueprint for distiling consequences of mutations within their pathophysiological context.

Indexed as

Down SyndromeEvolution, MolecularLeukemia, MyeloidTranscription, GeneticGATA1 Transcription FactorHumansLeukemoid ReactionMutationPhylogenySingle-Cell AnalysisSingle-Cell Gene Expression AnalysisTranscriptomeGATA1 protein, humanGATA1 Transcription Factor

Identifiers

PMID42026063
PMCPMC13106683

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.